Medical Packaging Transition Project Data | DuPont™ Tyvek®

DuPont is investing more than $30 million in the Tyvek® Medical Packaging Transition Project (MPTP) to ensure continuity and flexibility of future supply. To assist medical device manufacturers with their risk assessments, we post specific Tyvek® transition project information on this website as it becomes available.

The U.S. FDA has affirmed functional equivalence for Transition Tyvek® and has notified the industry of this news

WEBINAR: To download the slides from the latest Medical Packaging Transition Project webinar held on October 6, please click here

DuPont™ Tyvek® Medical Packaging Transition Project (MPTP)

Medical Packaging Transition Project Industry Reports

Transition Tyvek® and Legacy Tyvek® Property Data

DuPont™ Tyvek® Transition Material Property Data

DuPont™ Tyvek® Transition Material Additional Testing (Phantom Protocol Testing)

Biocompatibility, Food Contact and Pharmacopeia Results

U.S. FDA Protocol Package Data
Data will be published as available

Phantom Protocol Package Data
Data will be published as available

Developmental Material Data

Regulatory Guidance

In addition to Tyvek® transition project data, guidance obtained from regulatory authorities around the world is posted to help medical device manufacturers stay informed. For more information on regulatory letters, testing certificates, as well as Device Master Files, please visit our Medical Packaging Reference Library.

- Guidance from U.S. F.D.A. 

- Regulatory Guidance from Japan

Summary of Guidance from China, CFDA-Jinan

- Guidance from Health Canada


European Notified Bodies

- Position Statements with Protocol Review

- Position Statements

Resources